Nirmal Mulye, Ph.D., is the Founder and Chairman of Nostrum Group of companies focused on energy and pharmaceutical sectors. The Nostrum Family of Companies includes Nostrum Energy, which is developing a high-efficiency internal combustion engine for power generation as well as automotive application, and a novel hydrokinetic device for power generation. Nostrum Energy has two subsidiaries, Nostrum Motors and Nostrum Power. Dr. Mulye founded Nostrum Pharmaceuticals, LLC (NPLLC) in 1995 to develop and commercialize prescription pharmaceuticals utilizing novel drug delivery technologies. NPLLC subsidiaries include: Nostrum Laboratories, Inc., which has a state of the art manufacturing plant in Kansas City, MO and markets several generic products in the U.S.; Symmetrix Biotech, Inc. which develops novel clot buster therapeutic proteins using recombinant DNA technology that has proved safe in human trials; Nostrum Technologies LLC develops medical devices as well as drug delivery devices for Idiopathic Pulmonary Fibrosis where currently lung transplant is the only other approved therapy; Kemxtree Inc. develops novel compounds for immune suppression used to prevent organ rejection in patients receiving transplants and for bone growth and treatment for osteoporosis, fracture healing, etc; EnEm Nostrum Pvt. Ltd. based in Mumbai, India , which is a fully-recognized research arm of Nostrum with a state-of-the-art research facility to conduct pharmaceutical and energy systems development.
1111 19th Street, NW #406, Washington, DC 20036